Company profile
Kaya Holdings, Inc.
OTC: KAYS · Healthcare · Drug Manufacturers - Specialty & Generic
#1143 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 18GM —SS 25
v0.1 · 25/100 weight · pillars only
↑ listing tenure, growth stability · ↓ balance-sheet leverage, workforce scale
Methodology →Revenue TTM
-$1.3k
Rev growth YoY (TTM)
-102.0%
Net income (FY)
-$2.1M
Employees
2
as of 2026-08-26
Market cap
$4.2k
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$7.1k$7.1k2024
Net income-$2.1M-$2.1M2024
Operating income-$2.0M-$2.0M2024
Total assets$216.4k$216.4k2024
Liabilities$17.3M$17.3M2024
Equity-$15.0M-$15.0M2024
Revenue trend
FY2020 – FY2024 · USD
FY20
FY20
FY22
FY22
FY23
FY24
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Kaya Holdings, Inc.’s revenue?
Kaya Holdings, Inc. booked $7.1k in FY2024 revenue, contracting 96% year over year — among the slowest-growing Healthcare companies we track, at a -29168.2% net margin.
Peers · Healthcare
Voyageur Pharmaceuticals Ltd.——Genelux Corporation32DBetter Therapeutics, Inc.——Aspire Biopharma Holdings, Inc.17DCreative Medical Technology Holdings, Inc.46DAlaunos Therapeutics, Inc.33DNeighbors
Broward →Key facts
CEOCraig R. Frank
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersFort Lauderdale, FL
ExchangeOTC: KAYS
Employees2
IPO date2012-08-28
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.